1. Pantel K, Brakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004;4:448-56.

2. Steeg PS. Targeting metastasis. Nat Rev Cancer 2016;16:201-18.

3. Fidler IJ, Kripke ML. The challenge of targeting metastasis. Cancer Metastasis Rev 2015;34:635-41.

4. Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer 2018;18:533-48.

5. Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer 2009;9:274-84.

6. Sethi N, Kang Y. Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer 2011;11:735-48.

7. Huang C, Jacobson K, Schaller MD. A role for JNK-paxillin signaling in cell migration. Cell Cycle 2004;3:4-6.

8. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci 2004;117:4619-28.

9. Huang Z, Yan DP, Ge BX. JNK regulates cell migration through promotion of tyrosine phosphorylation of paxillin. Cell Signal 2008;20:2002-12.

10. Le Devedec SE, van Roosmalen W, Maria N, Grimbergen M, Pont C, et al. An improved model to study tumor cell autonomous metastasis programs using MTLn3 cells and the Rag2(-/-) gammac (-/-) mouse. Clin Exp Metastasis 2009;26:673-84.

11. Omran OM, Al SM. Cytoskeletal focal adhesion proteins fascin-1 and paxillin are predictors of malignant progression and poor prognosis in human breast cancer. J Environ Pathol Toxicol Oncol 2015;34:201-12.

12. Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 2009;9:537-49.

13. Chen J, Gallo KA. MLK3 regulates paxillin phosphorylation in chemokine-mediated breast cancer cell migration and invasion to drive metastasis. Cancer Res 2012;72:4130-40.

14. Shin EY, Kim SY, Kim EG. c-Jun N-terminal kinase is involved in motility of endothelial cell. Exp Mol Med 2001;33:276-83.

15. Xia Y, Makris C, Su B, Li E, Yang J, et al. MEK kinase 1 is critically required for c-Jun N-terminal kinase activation by proinflammatory stimuli and growth factor-induced cell migration. Proc Natl Acad Sci U S A 2000;97:5243-8.

16. Kavurma MM, Khachigian LM. ERK, JNK, and p38 MAP kinases differentially regulate proliferation and migration of phenotypically distinct smooth muscle cell subtypes. J Cell Biochem 2003;89:289-300.

17. Kawauchi T, Chihama K, Nabeshima Y, Hoshino M. The in vivo roles of STEF/Tiam1, Rac1 and JNK in cortical neuronal migration. EMBO J 2003;22:4190-201.

18. Zhang L, Wang W, Hayashi Y, Jester JV, Birk DE, et al. A role for MEK kinase 1 in TGF-beta/activin-induced epithelium movement and embryonic eyelid closure. EMBO J 2003;22:4443-54.

19. Berginski ME, Vitriol EA, Hahn KM, Gomez SM. High-resolution quantification of focal adhesion spatiotemporal dynamics in living cells. PLoS One 2011;6:e22025.

20. Guo L, Guo Y, Xiao S, Shi X. Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci 2005;77:1869-78.

21. Yin Y, Wang S, Sun Y, Matt Y, Colburn NH, et al. JNK/AP-1 pathway is involved in tumor necrosis factor-alpha induced expression of vascular endothelial growth factor in MCF7 cells. Biomed Pharmacother 2009;63:429-35.

22. Kappelmann M, Bosserhoff A, Kuphal S. AP-1/c-Jun transcription factors: regulation and function in malignant melanoma. Eur J Cell Biol 2014;93:76-81.

23. Lee MH, Koria P, Qu J, Andreadis ST. JNK phosphorylates beta-catenin and regulates adherens junctions. FASEB J 2009;23:3874-83.

24. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature 2003;424:219-23.

25. Miyamoto Y, Torii T, Yamamori N, Eguchi T, Nagao M, et al. Paxillin is the target of c-Jun N-terminal kinase in Schwann cells and regulates migration. Cell Signal 2012;24:2061-9.

26. Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol 2000;2:E231-6.

27. Turner CE. Paxillin interactions. J Cell Sci 2000;113 Pt 23:4139-40.

28. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006;18:516-23.

29. Zaidel-Bar R, Itzkovitz S, Ma'ayan A, Iyengar R, Geiger B. Functional atlas of the integrin adhesome. Nat Cell Biol 2007;9:858-67.

30. Huveneers S, Danen EH. Adhesion signal. J Cell Sci 2009;122:1059-69.

31. Harburger DS, Calderwood DA. Integrin signalling at a glance. J Cell Sci 2009;122:159-63.

32. Tumbarello DA, Brown MC, Turner CE. The paxillin LD motifs. FEBS Lett 2002;513:114-8.

33. Schaller MD. Paxillin: a focal adhesion-associated adaptor protein. Oncogene 2001;20:6459-72.

34. Brown MC, Turner CE. Paxillin: adapting to change. Physiol Rev 2004;84:1315-39.

35. Deakin NO, Turner CE. Paxillin comes of age. J Cell Sci 2008;121:2435-44.

36. Lopez-Colome AM, Lee-Rivera I, Benavides-Hidalgo R, Lopez E. Paxillin: a crossroad in pathological cell migration. J Hematol Oncol 2017;10:50.

37. Hammes SR, Miedlich SU, Sen A. Paxillin and steroid signaling: from frog to human. Methods Mol Biol 2014;1204:95-108.

38. Ma X, Hammes SR. Paxillin actions in the nucleus. Steroids 2018;133:87-92.

39. Cai J, Du S, Wang H, Xin B, Wang J, et al. Tenascin-C induces migration and invasion through JNK/c-Jun signalling in pancreatic cancer. Oncotarget 2017;8:74406-22.

40. Chen J, Miller EM, Gallo KA. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells. Oncogene 2010;29:4399-411.

41. Rattanasinchai C, Llewellyn BJ, Conrad SE, Gallo KA. MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells. Oncogenesis 2017;6:e345.

42. Huigsloot M, Tijdens IB, Mulder GJ, van de WB. Differential regulation of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary adenocarcinoma (MTLn3) cells. J Biol Chem 2002;277:35869-79.

43. Xue C, Wyckoff J, Liang F, Sidani M, Violini S, et al. Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res 2006;66:192-7.

44. Vasanwala FH, Kusam S, Toney LM, Dent AL. Repression of AP-1 function: a mechanism for the regulation of Blimp-1 expression and B lymphocyte differentiation by the B cell lymphoma-6 protooncogene. J Immunol 2002;169:1922-9.

45. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 2013;14:128.

46. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 2016;44:W90-7.

47. Rosse C, Formstecher E, Boeckeler K, Zhao Y, Kremerskothen J, et al. An aPKC-exocyst complex controls paxillin phosphorylation and migration through localised JNK1 activation. PLoS Biol 2009;7:e1000235.

48. de Graauw M, Tijdens I, Cramer R, Corless S, Timms JF, et al. Heat shock protein 27 is the major differentially phosphorylated protein involved in renal epithelial cellular stress response and controls focal adhesion organization and apoptosis. J Biol Chem 2005;280:29885-98.

49. Yamanaka I, Koizumi M, Baba T, Yamashita S, Suzuki T, et al. Epidermal growth factor increased the expression of alpha2beta1-integrin and modulated integrin-mediated signaling in human cervical adenocarcinoma cells. Exp Cell Res 2003;286:165-74.

50. Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, et al. Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res 2009;69:1383-91.

51. Lu Z, Jiang G, Blume-Jensen P, Hunter T. Epidermal growth factor-induced tumor cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion kinase. Mol Cell Biol 2001;21:4016-31.

52. Thelemann A, Petti F, Griffin G, Iwata K, Hunt T, et al. Phosphotyrosine signaling networks in epidermal growth factor receptor overexpressing squamous carcinoma cells. Mol Cell Proteomics 2005;4:356-76.

53. Johnson AC, Murphy BA, Matelis CM, Rubin stein Y, Piebenga EC, et al. Activator protein-1 mediates induced but not basal epidermal growth factor receptor gene expression. Mol Med 2000;6:17-27.

54. Zenz R, Scheuch H, Martin P, Frank C, Eferl R, et al. c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell 2003;4:879-89.

55. Kimura K, Teranishi S, Yamauchi J, Nishida T. Role of JNK-dependent serine phosphorylation of paxillin in migration of corneal epithelial cells during wound closure. Invest Ophthalmol Vis Sci 2008;49:125-32.

56. Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, et al. P21-activated protein kinase is overexpressed in hepatocellular carcinoma and enhances cancer metastasis involving c-Jun NH2-terminal kinase activation and paxillin phosphorylation. Cancer Res 2007;67:3601-8.

57. Smadja-Lamere N, Boulanger MC, Champagne C, Branton PE, Lavoie JN. JNK-mediated phosphorylation of paxillin in adhesion assembly and tension-induced cell death by the adenovirus death factor E4orf4. J Biol Chem 2008;283:34352-64.

58. Yamauchi J, Miyamoto Y, Sanbe A, Tanoue A. JNK phosphorylation of paxillin, acting through the Rac1 and Cdc42 signaling cascade, mediates neurite extension in N1E-115 cells. Exp Cell Res 2006;312:2954-61.

59. Rattanasinchai C, Llewellyn BJ, Conrad SE, Gallo KA. MLK3 regulates FRA-1 and MMPs to drive invasion and transendothelial migration in triple-negative breast cancer cells. Oncogenesis 2017;6:e345.

60. Kim DY, Helfman DM. Loss of MLCK leads to disruption of cell-cell adhesion and invasive behavior of breast epithelial cells via increased expression of EGFR and ERK/JNK signaling. Oncogene 2016;35:4495-508.

61. Madshus IH, Stang E. Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking. J Cell Sci 2009;122:3433-9.

62. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004;117:5965-73.

63. Ishibe S, Joly D, Zhu X, Cantley LG. Phosphorylation-dependent paxillin-ERK association mediates hepatocyte growth factor-stimulated epithelial morphogenesis. Mol Cell 2003;12:1275-85.

64. Ishibe S, Joly D, Liu ZX, Cantley LG. Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis. Mol Cell 2004;16:257-67.

65. Woods AJ, Roberts MS, Choudhary J, Barry ST, Mazaki Y, et al. Paxillin associates with poly(A)-binding protein 1 at the dense endoplasmic reticulum and the leading edge of migrating cells. J Biol Chem 2002;277:6428-37.

66. Lewis JM, Baskaran R, Taagepera S, Schwartz MA, Wang JY. Integrin regulation of c-Abl tyrosine kinase activity and cytoplasmic-nuclear transport. Proc Natl Acad Sci U S A 1996;93:15174-9.

67. Lewis JM, Schwartz MA. Integrins regulate the association and phosphorylation of paxillin by c-Abl. J Biol Chem 1998;273:14225-30.

68. Hervy M, Hoffman L, Beckerle MC. From the membrane to the nucleus and back again: bifunctional focal adhesion proteins. Curr Opin Cell Biol 2006;18:524-32.

69. Sathe AR, Shivashankar GV, Sheetz MP. Nuclear transport of paxillin depends on focal adhesion dynamics and FAT domains. J Cell Sci 2016;129:1981-8.

70. Sen A, De Castro I, DeFranco DB, Deng FM, Melamed J, et al. Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. J Clin Invest 2012;122:2469-81.

71. Wang Y, Gilmore TD. Zyxin and paxillin proteins: focal adhesion plaque LIM domain proteins go nuclear. Biochim Biophys Acta 2003;1593:115-20.

72. Bubici C, Papa S. JNK signalling in cancer: in need of new, smarter therapeutic targets. Br J Pharmacol 2014;171:24-37.

73. Kumar A, Singh UK, Kini SG, Garg V, Agrawal S, et al. JNK pathway signaling: a novel and smarter therapeutic targets for various biological diseases. Future Med Chem 2015;7:2065-86.

Journal of Cancer Metastasis and Treatment
ISSN 2454-2857 (Online) 2394-4722 (Print)


All published articles are preserved here permanently:


All published articles are preserved here permanently: